When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting

摘要: Background: The COU-AA 301 trial showed that AA improved survival for men with mCRPC progressing to docetaxel. No predictive factors are available to identify patients (pts) that may better respond to AA. In this trial the median duration of drug exposure was 7.4 months (range 0.2-25.6). Our aim was to describe clinical features of pts long responding to AA defined as those receiving AA in clinical practice for more than 12 months without evidence of disease progression.Patients and methods: A total of 143 mCRPC pts treated with AA for more than 12 months at 16 Italian centers from Oct 2011 to Jul 2014 were identified. Clinical records were retrospectively collected and analyzed. Descriptive statistics (median and range for continuous variables and absolute and percentage frequencies for categorical variables) were used to describe clinical features; the Cox regression model was used to detect and estimate …